This Is the Most Important Number From Novavax's Q1 Earnings
The big news for Novavax (NASDAQ: NVAX) investors this week was that the company reported its first-ever quarterly profit. The COVID-19 vaccine maker delivered a strong top line which led to a whopping $203 million profit for the first three months of the year, which was a big reversal from the $223 million loss that it incurred in the same quarter of 2021.
However, despite the seemingly positive results, the stock initially fell as its revenue fell short of analyst expectations. But I'd argue that neither the top nor bottom line is what investors should be focused on right now.
Image source: Getty Images.
Source Fool.com
